Use of a chemotherapeutic Agent, which comprises (a) an effective amount of a reovirus and (b) an effective amount of the chemotherapeutic Agent to the cell, which is for the manufacture of a Medicament for the sensitization of a cancer cell.Claim 6: the method of claim 1, in which the chemotherapeutic Agent selected from the group consisting mitomicin C, 5-fluorouracil, cyclophosphamide, methotrexate, Hydroxyurea, dacarbazine, anthracyclines, Mitoxantrone, etoposide, cisplatin, Taxol, TAXOTERE, tamoxif In, anti estrogens and interferons.Claim 1: the method of claim 10, in which the reovirus Serotype 3 is a reovirus Strain Dearing.Claim 12: a method for treating a subject with a proliferative Disorder, in which the subject comprises neoplastic cells that are Refractory to a chemotherapeutic Agent,Comprising: (a) administering to the subject an effective amount of reovirus in conditions that result in an infection of neoplastic cells by reovirus and (b) administering an effective amount of the chemotherapeutic Agent to that subject. The Method of claim 19: 12 the claim, which is a solid tumor proliferative disorder.The Method of claim claim 20: 19, in which the solid tumor is selected from the group consisting of Lung Cancer, prostate cancer, colorectal cancer, Thyroid cancer, renal cancer, adrenal cancer, liver cancer, pancreatic cancer, Breast Cancer and C Cancer of the Central and Peripheral nervous system.Uso de un agente quimioterapéutico, que comprende: (a) una cantidad efectiva de un reovirus y (b) una cantidad efectiva del agente quimioterapéutico a dicha célula, que es para la manufactura de un medicamento para la sensibilización de una célula neoplásica. Reivindicación 6: El método de la reivindicación 1, en la cual el agente quimioterapéutico se selecciona del grupo que consiste en 5-fluorouracilo, mitomicin C, metotrexate, hidroxiurea, ciclofosfamide, dacarbazine, mitoxantrone, antraciclinas, carboplatino, cisplatino, taxol, taxotere, tamoxifen, anti-estr
